Pacylex Pharmaceuticals Reports Safety and Efficacy Results from Its Phase 1 First-In-Human Study of Zelenirstat (PCLX-001)

On November 30, 2023 Pacylex Pharmaceuticals Inc. (Pacylex), a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies for the treatment of hematologic and solid tumor cancers, reported that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex’s lead product candidate, will be included in investor updates presented at upcoming conferences in December and January (Press release, Pacylex Pharmaceuticals, NOV 30, 2023, View Source [SID1234645054]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 dose escalation safety and tolerability study was conducted in 29 lymphoma and solid tumor patients, who averaged 4 prior lines of therapy to which they were relapsed or refractor (R/R). The most common treatment related adverse events identified in the trial were mild to moderate gastrointestinal side effects which were self-limiting and occurred in a minority of patients. A recommended Phase 2 dose for expansion studies was established. Zelenirstat unexpectedly prolonged progression free survival in some Phase 1 solid tumor patients receiving the recommended Phase 2 dose; several patients at this dose continue zelenirstat treatment for up to ten 28-day cycles and counting. The Company has commenced a Phase 2a expansion study in patients with B-cell non-Hodgkin lymphoma.

Dr. Michael Weickert, Ph.D., Pacylex’s Chief Executive Officer, will present a corporate overview and discuss the Company’s Phase 1 study safety results and efficacy signals as well as development plans for this potential first-in-class oral therapy, at two upcoming investment conferences:

MedInvest Oncology Investor Conference on December 5-6, 2023 in Palo Alto, CA and present Phase 1 safety, tolerability and efficacy results for zelenirstat on Tuesday December 5, 2023 at 11:10 AM PT.
Pacylex will also participate in Biotech Showcase a premier investor and networking conference on January 8-10, 2024, alongside the JP Morgan Healthcare Conference. Dr. Weickert will present an update on the clinical progress of zelenirstat at the meeting in San Francisco, CA.
Dr. Weickert will also be available for one-on-one meetings at both conferences.

"The safety profile for zelenirstat is consistent with advancement to Phase 2 but the surprise in this study were the benefits observed in patients with heavily pre-treated solid tumors," said Dr. John Mackey, Chief Medical Officer for Pacylex and a practicing oncologist. "The fact that several patients receiving the Phase 2 dose have been treated with zelenirstat longer than any prior therapy, with reductions in disease burden, is very encouraging."

"We are delighted to attend these two premier investor conferences to showcase our Phase 1 study results, where zelenirstat demonstrated an acceptable safety and tolerability profile, favorable pharmacokinetics, and early efficacy signals," said Dr. Michael Weickert, CEO of Pacylex. "These better-than-expected Phase 1 results give us a sense of urgency to evaluate zelenirstat in a broader group of patients than initially planned."

Those interested in requesting a one-on-one meeting at the MedInvest Conference can submit a registration request using the conference website HERE. Presentation materials will be available under the News section of Pacylex’s website HERE.

Registered attendees of Biotech Showcase can request a one-on-one meeting with Dr. Weickert using the partneringONE platform HERE. If there are no compatible time slots available, please contact Dr. Weickert directly to schedule a meeting.

About zelenirstat (PCLX-001)

Zelenirstat (formerly identified as PCLX-001) is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia, lymphoma, and solid tumors. In animal models, zelenirstat selectively killed cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors. In AML models, zelenirstat killed leukemic stem enriched cell populations and allowed the regeneration and growth of normal bone marrow cells.

About zelenirstat Phase 1 and 2 studies

Pacylex completed the dose escalation phase of a Phase 1 multiple ascending dose safety, tolerability, and pharmacokinetics study on zelenirstat in R/R lymphoma and solid tumor patients (NCT04836195). A recommended Phase 2 dose was determined. Zelenirstat demonstrated an acceptable safety and tolerability profile, pharmacokinetics consistent with once daily oral dosing, and early signs of potential efficacy.

Zelenirstat is currently being studied in a Phase 2a open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of zelenirstat in patients with R/R B-cell non-Hodgkin Lymphoma (NHL). A separate Phase 2a cohort is planned in advanced solid malignancies who have progressed on all available standard therapies.

Cello Therapeutics Received IND Clearance by FDA for its First-in-Class Cellular Nanoparticle (CNP) based Immunotherapy, CE120, to Enter Clinical Phase.

On November 30, 2023 Cello Therapeutics, Inc. reported to have received IND clearance from the U.S. Food and Drug Administration (FDA) for its first immunotherapy nanoformulation CE120 to initiate first-in-human clinical trials for a variety of solid tumors (Press release, Cello Therapeutics, NOV 30, 2023, View Source [SID1234638189]). CE120 is the first innovative nanomedicine cleared for clinical trials that employs platelet membrane-coated nanoparticles for drug delivery, offering a dual benefit of tumor elimination and the potential for long-term cancer immunity in patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CE120 is a broad-spectrum therapeutic cancer nanovaccine developed by Cello Therapeutics, Inc. based on the Cellular Nanoparticle (CNP) drug delivery technology platform with independent intellectual property rights, and the biomimetic design concept. CE120 comprises an enriched platelet cell membrane coating on polymeric nanoparticles carrying a potent immunotherapy drug. Leveraging the inherent biological functionality of platelets, CE120 achieves targeted delivery and prolonged residence within tumor tissues after local administration. Through a gradual drug release mechanism, CE120 effectively triggers the body’s anti-tumor immune response, addressing issues associated with poor therapeutic outcomes, safety concerns, and side effects linked to excessive systemic exposure.

Cello Therapeutics, Inc. (Cello) is a leading biomedical company focused on developing novel nanoparticle delivery platforms for cancer treatment. Our cellular nanoparticles (CNPs) are comprised of three main components—drug payload, biocompatible polymer, and natural cellular membrane. The payload could be a chemotherapy or immunomodulatory agent, mRNA or siRNA. The drugs are loaded within the biodegradable polymer core, which is then coated with membrane derived from human cells. This cell membrane coating technology is a recent breakthrough in the field of nanomedicine. Our target is to treat all types of cancers with a single delivery platform.

Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection

On November 30, 2023 Guardant Health, a leading precision oncology company, reported the company will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas (Press release, Guardant Health, NOV 30, 2023, View Source [SID1234638083]). Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual disease and predict recurrence in patients with early-stage breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing new data in San Antonio demonstrating the utility of liquid biopsy in advancing the practice of precision oncology for patients with breast cancer," said Craig Eagle, Guardant Health chief medical officer. "The presentations will show how comprehensive genomic profiling and residual disease detection using blood-based testing provide critical insights to help oncologists develop personalized treatment plans that can improve patient outcomes."

Two studies were selected for spotlight discussions:

The PlasmaMATCH study assessed the feasibility of ctDNA genomic profiling for actionable biomarker detection and therapy selection in patients with advanced breast cancer. This research explores the use of ctDNA at multiple points in time to predict therapy response in patients on targeted therapy, including establishing thresholds that best predict clinical outcomes. Study results show the use of longitudinal sampling and ctDNA assessment may help in understanding, predicting and preparing for clinical outcomes in patients receiving systemic therapy.
In a large feasibility study of over 300 patients with early-stage breast cancer, samples were collected about two years after curative-intent adjuvant chemotherapy and tested with Guardant Reveal, using epigenomic technology to assess for the presence of ctDNA. The study found ctDNA detection after adjuvant therapy was prognostic for distant recurrence, with a median lead time between detection and clinically observed disease recurrence of 7.9 months and high specificity. The study also notes that ctDNA was detected up to 28.6 months prior to clinical recurrence detection.
Guardant Health poster presentations

Guardant360 and GuardantOMNI

The prognostic and predictive impact of circulating tumor DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial (Poster spotlight discussion PS06-04)
Guardant360 CDx

Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients enrolled in the German registry study PRAEGNANT (Poster P04-05-03)
Guardant360

CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer (Poster GS01-08)
Enhancing Informative Outcomes with Liquid Biopsy in a Real-World Population of Patients with Advanced Breast Cancer: Analysis of the SOLTI-1903 HOPE Study (Poster P04-14-02)
Detection of SPEN mutations in advanced breast cancer by circulating tumor cell-free DNA (Poster P05-14-07)
Guardant Reveal

Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer (Poster spotlight discussion PS06-06)
Guardant INFORM

A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (mBC) ( Poster PO1-23-09)
Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC) (Poster P04-18-02)
The full abstracts are available on the official SABCS 2023 website.

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

On November 30, 2023 Gilead Sciences, Inc. (Nasdaq: GILD) reported it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data featured in eight presentations include an analysis of clinical outcomes by age from the Phase 3 TROPiCS-02 study of Trodelvy in HR+/HER2- mBC, as well as a qualitative analysis of the experiences and perspectives of patients, caregivers and clinicians on clinical meaningfulness in mBC treatment decision-making. The study adds to a needed body of research exploring the importance of patient-centered interpretations of clinical meaningfulness (e.g., survival, quality of life).

"Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer," said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. "The data being presented at SABCS add to the breadth of evidence reinforcing Trodelvy’s use in these two difficult-to-treat breast cancers. Additionally, the real-world data being presented in metastatic breast cancer provide insights on quality of life and other measures of health to inform both providers and patients in making treatment decisions."

Table of Accepted Abstracts (all times CDT):

Abstract Disposition

Abstract Title

Poster # PO1-05-09

Wednesday, Dec. 6

12:00 PM

ASCENT-07: A Phase 3, Randomized, Open-Label Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post-Endocrine Therapy

Poster # PO1-06-10

Wednesday, Dec. 6

12:00 PM

Overall Survival Results From EVER-132-001, a Phase 2B Single-Arm Study of Sacituzumab Govitecan in Chinese Patients with Metastatic Triple-Negative Breast Cancer

Poster # PO1-04-06

Wednesday, Dec. 6

12:00 PM

Exposure-response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients with Metastatic Breast Cancer

Poster # PO1-06-08

Wednesday, Dec. 6

12:00 PM

Treatment Utilization by Race and Insurance Type Among TNBC Patients

Poster # PO1-10-06

Wednesday, Dec. 6

12:00 PM

Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians

Poster # PO2-05-03

Wednesday, Dec. 6

5:00 PM

Costs Associated with Adverse Events in Patients Receiving Treatment for Hormone Receptor Positive/Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer

Poster # PO2-05-02

Wednesday, Dec. 6

5:00 PM

Real-World Experience of Patients Receiving Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer: A Global Analysis of Symptoms and Side Effects

Poster # PO5-21-09

Friday, Dec. 8

12:00 PM

Clinical Outcomes by Age Subgroups in the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in HR+/HER2‒ Metastatic Breast Cancer

Trodelvy is recommended as a category 1 preferred treatment for second-line mTNBC and a category 1 preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network (NCCN) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines).1

About Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.

Trodelvy is approved in almost 50 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Trodelvy is also approved in the U.S., the European Union, and multiple other global markets to treat certain patients with pre-treated HR+/HER2- metastatic breast cancer. In the U.S., Trodelvy also has accelerated approval for treatment of certain patients with second-line metastatic urothelial cancer (UC); see below for the full U.S. indication for Trodelvy.

Trodelvy is also being developed for potential investigational use in other TNBC, HR+/HER2- and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.

U.S. Indications for Trodelvy

In the United States, Trodelvy is indicated for the treatment of adult patients with:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. Important Safety Information for Trodelvy

BOXED WARNING: NEUTROPENIA AND DIARRHEA

Severe or life-threatening neutropenia may occur. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold Trodelvy until resolved to ≤Grade 1 and reduce subsequent doses.
CONTRAINDICATIONS

Severe hypersensitivity reaction to Trodelvy.
WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 64% of patients treated with Trodelvy. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever. Administer G-CSF as clinically indicated or indicated in Table 1 of USPI.

Diarrhea: Diarrhea occurred in 64% of all patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of Trodelvy was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions.

Nausea and Vomiting: Nausea occurred in 64% of all patients treated with Trodelvy and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Trodelvy and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).

In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.

In the TROPHY study (locally advanced or metastatic urothelial cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, any infection, alopecia, decreased appetite, constipation, vomiting, rash, and abdominal pain. The most frequent serious adverse reactions (SAR) (≥5%) were infection (18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy.

UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy.

Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations

On November 30, 2023 Median Technologies reported that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being held in Chicago (Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3 (Press release, MEDIAN Technologies, NOV 30, 2023, View Source [SID1234638081]). The NACLC is organized by the International Association for the Study of Lung Cancer (IASLC), a global multidisciplinary association dedicated to eradication of all forms of lung cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will give two poster presentations on December 2nd from 5:40 to 6:55 pm CT.

Poster PP01.49: End to End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis

Poster PP01.44: A CT Imaging Biomarker for CD8+ Lymphocytes Infiltration Stratification in Patients with Non-Small Cell Lung Cancer

Median’s eyonis and Imaging Lab teams will attend the event and be available for presenting the latest advances of eyonis AI/ML tech based SaMD and the Imaging Lab developments.